SAN DIEGO–(BUSINESS WIRE)–Turning Point Therapeutics, Inc., a clinical-stage precision oncology
company developing novel drugs that address treatment resistance,
announced today the appointment of Annette C. North as executive vice
president and general counsel, effective April 15. In this role, Ms.
North will also serve as company secretary.
“Annette brings a wealth of experience and depth to our growing
management team through 25 years serving biotechnology companies from
inception through private and public fundraising, business development,
and mergers and acquisitions,” said Athena Countouriotis, M.D., chief
executive officer. “On a personal note, I have known Annette for many
years and am happy to work with her again as we execute our plans for
multiple potentially transformational cancer therapies.”
Ms. North has served as a senior executive and general counsel for a
number of prior biotechnology companies, most recently Kura Oncology and
Wellspring Biosciences. At Kura, she was responsible for all legal
affairs, including corporate governance and compliance, intellectual
property, the company’s financings and public listing on the NASDAQ
stock market, and initiation of a pivotal global clinical trial. Prior
to Kura, Ms. North served as senior vice president and general counsel
at Ambit Biosciences from initial public offering and initiation of a
pivotal global clinical trial through acquisition by Daiichi Sankyo.
Prior to Ambit, she held legal roles at SGX Pharmaceuticals, Axys
Pharmaceuticals, Sequana Therapeutics, and private law firms.
“Turning Point provides a unique opportunity for me to work again with
Athena -– a talented and dynamic leader who I have known for many years
— on a pipeline of potentially transformational therapies,” said Ms.
North. “From the scientific founders to the team Athena has attracted,
this is an impressive group of professionals with a strong connection to
cancer patients and prior track records of success in bringing new
therapies to market. I am excited to become part of the team.”
Ms. North earned her Bachelor of Laws and Bachelor of Commerce degrees
from Melbourne University in Australia, and is a member of the State Bar
of California.
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology
company with a pipeline of internally discovered investigational drugs
designed to address key limitations of existing cancer therapies. The
company’s lead program, repotrectinib, is a next-generation kinase
inhibitor targeting genetic drivers of non-small cell lung cancer and
advanced solid tumors. Repotrectinib has shown antitumor activity and
durable responses among kinase inhibitor treatment-naïve and pre-treated
patients, and is planned to enter a registrational Phase 2 study in the
second half of 2019. Turning Point’s kinase inhibitors are designed to
bind to their targets with greater precision and affinity than existing
therapies, with a novel, compact structure that has demonstrated an
ability to potentially overcome treatment resistance common with other
kinase inhibitors. The company is driven to develop therapies that mark
a turning point for patients in their cancer treatment. For more
information, visit www.tptherapeutics.com.
Contacts
Jim Mazzola
jim.mazzola@tptherapeutics.com
858-342-8272